Astellas Pharma Inc
TSE:4503

Watchlist Manager
Astellas Pharma Inc Logo
Astellas Pharma Inc
TSE:4503
Watchlist
Price: 1 562 JPY -0.64% Market Closed
Market Cap: 2.8T JPY
Have any thoughts about
Astellas Pharma Inc?
Write Note

Intrinsic Value

The intrinsic value of one Astellas Pharma Inc stock under the Base Case scenario is 1 795.96 JPY. Compared to the current market price of 1 562 JPY, Astellas Pharma Inc is Undervalued by 13%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

Intrinsic Value
1 795.96 JPY
Undervaluation 13%
Intrinsic Value
Price
Base Case Scenario

Valuation Backtest
Astellas Pharma Inc

Backtest Intrinsic Value
Dive into the past to invest in the future

Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start backtest now and learn if your stock is truly undervalued or overvalued!

Run Backtest
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
Register to View Results
Register to View Results

To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.

Backtest Unavailable

The backtest for Astellas Pharma Inc cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.

Backtest In Progress...
Backtest In Progress...
How do you feel about Astellas Pharma Inc?
Bearish
Neutral
Bullish

Fundamental Analysis

Economic Moat
Astellas Pharma Inc

Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

Investment Journal
AI Assistant
AI Assistant
Ask me anything about Astellas Pharma Inc

Provide an overview of the primary business activities
of Astellas Pharma Inc.

What unique competitive advantages
does Astellas Pharma Inc hold over its rivals?

What risks and challenges
does Astellas Pharma Inc face in the near future?

Summarize the latest earnings call
of Astellas Pharma Inc.

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Astellas Pharma Inc.

Provide P/S
for Astellas Pharma Inc.

Provide P/E
for Astellas Pharma Inc.

Provide P/OCF
for Astellas Pharma Inc.

Provide P/FCFE
for Astellas Pharma Inc.

Provide P/B
for Astellas Pharma Inc.

Provide EV/S
for Astellas Pharma Inc.

Provide EV/GP
for Astellas Pharma Inc.

Provide EV/EBITDA
for Astellas Pharma Inc.

Provide EV/EBIT
for Astellas Pharma Inc.

Provide EV/OCF
for Astellas Pharma Inc.

Provide EV/FCFF
for Astellas Pharma Inc.

Provide EV/IC
for Astellas Pharma Inc.

Show me price targets
for Astellas Pharma Inc made by professional analysts.

What are the Revenue projections
for Astellas Pharma Inc?

How accurate were the past Revenue estimates
for Astellas Pharma Inc?

What are the Net Income projections
for Astellas Pharma Inc?

How accurate were the past Net Income estimates
for Astellas Pharma Inc?

What are the EPS projections
for Astellas Pharma Inc?

How accurate were the past EPS estimates
for Astellas Pharma Inc?

What are the EBIT projections
for Astellas Pharma Inc?

How accurate were the past EBIT estimates
for Astellas Pharma Inc?

Compare the revenue forecasts
for Astellas Pharma Inc with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Astellas Pharma Inc and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Astellas Pharma Inc against its competitors.

Analyze the profit margins
(gross, operating, and net) of Astellas Pharma Inc compared to its peers.

Compare the P/E ratios
of Astellas Pharma Inc against its peers.

Discuss the investment returns and shareholder value creation
comparing Astellas Pharma Inc with its peers.

Analyze the financial leverage
of Astellas Pharma Inc compared to its main competitors.

Show all profitability ratios
for Astellas Pharma Inc.

Provide ROE
for Astellas Pharma Inc.

Provide ROA
for Astellas Pharma Inc.

Provide ROIC
for Astellas Pharma Inc.

Provide ROCE
for Astellas Pharma Inc.

Provide Gross Margin
for Astellas Pharma Inc.

Provide Operating Margin
for Astellas Pharma Inc.

Provide Net Margin
for Astellas Pharma Inc.

Provide FCF Margin
for Astellas Pharma Inc.

Show all solvency ratios
for Astellas Pharma Inc.

Provide D/E Ratio
for Astellas Pharma Inc.

Provide D/A Ratio
for Astellas Pharma Inc.

Provide Interest Coverage Ratio
for Astellas Pharma Inc.

Provide Altman Z-Score Ratio
for Astellas Pharma Inc.

Provide Quick Ratio
for Astellas Pharma Inc.

Provide Current Ratio
for Astellas Pharma Inc.

Provide Cash Ratio
for Astellas Pharma Inc.

What is the historical Revenue growth
over the last 5 years for Astellas Pharma Inc?

What is the historical Net Income growth
over the last 5 years for Astellas Pharma Inc?

What is the current Free Cash Flow
of Astellas Pharma Inc?

Discuss the annual earnings per share (EPS)
trend over the past five years for Astellas Pharma Inc.

Business Breakdown

Astellas Pharma Inc., a prominent player in the global pharmaceutical industry, has a clear mission: to improve the health of people around the world through innovative technologies and high-quality products. Founded in 2005 from the merger of Yamanouchi Pharmaceutical Co., Ltd. and Fujisawa Pharmaceutical Co., Ltd., Astellas has established itself as a leader in areas such as urology, oncology, immunology, and neuroscience. With strong research and development capabilities, the company invests heavily in developing groundbreaking therapies that address unmet medical needs, positioning itself at the forefront of advancements in health sciences. Astellas prides itself on its commitment to sus...

Read More
Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Astellas Pharma Inc

Current Assets 1.2T
Cash & Short-Term Investments 338.6B
Receivables 600B
Other Current Assets 302B
Non-Current Assets 2.5T
Long-Term Investments 132.9B
PP&E 309.7B
Intangibles 1.9T
Other Non-Current Assets 105.4B
Current Liabilities 1.4T
Accounts Payable 173.1B
Other Current Liabilities 1.2T
Non-Current Liabilities 685.3B
Long-Term Debt 443.1B
Other Non-Current Liabilities 242.2B
Efficiency

Earnings Waterfall
Astellas Pharma Inc

Revenue
2.1T JPY
Cost of Revenue
-383.6B JPY
Gross Profit
1.7T JPY
Operating Expenses
-1.6T JPY
Operating Income
130.6B JPY
Other Expenses
-75.9B JPY
Net Income
54.6B JPY

Free Cash Flow Analysis
Astellas Pharma Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
Earnings Calls

Astellas Pharma's Q1 FY 2024 results show revenue increased by 26% year-on-year to JPY 473.1 billion, driven by strong performance in the US. XTANDI sales rose by 29%, contributing significantly. Strategic brands like PADCEV and IZERVAY saw exponential growth, increasing overall strategic brand sales to JPY 75 billion, a threefold increase. Core operating profit also increased by 20.5%, reaching JPY 88.3 billion. Despite the foreign exchange impacts, both revenue and profit grew substantially. The company remains focused on efficient cost management and ROI-driven investments, expecting continued growth throughout the fiscal year.

What is Earnings Call?
Fundamental Scores

Profitability Score
Profitability Due Diligence

Astellas Pharma Inc's profitability score is 55/100. The higher the profitability score, the more profitable the company is.

Positive Gross Profit
Positive Free Cash Flow
Positive 3-Years Revenue Growth
Exceptional 1-Year Revenue Growth
55/100
Profitability
Score

Astellas Pharma Inc's profitability score is 55/100. The higher the profitability score, the more profitable the company is.

Solvency Score
Solvency Due Diligence

Astellas Pharma Inc's solvency score is 53/100. The higher the solvency score, the more solvent the company is.

Low D/E
Long-Term Solvency
Positive Net Debt
Short-Term Solvency
53/100
Solvency
Score

Astellas Pharma Inc's solvency score is 53/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

Price Targets Summary
Astellas Pharma Inc

Wall Street analysts forecast Astellas Pharma Inc stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for Astellas Pharma Inc is 1 983.56 JPY with a low forecast of 1 414 JPY and a high forecast of 2 520 JPY.

Lowest
Price Target
1 414 JPY
9% Downside
Average
Price Target
1 983.56 JPY
27% Upside
Highest
Price Target
2 520 JPY
61% Upside
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for Astellas Pharma Inc?

Click here to dive deeper.

Dividends

Dividend Yield
Lowest
Average
Highest
Dividend Per Share
N/A
Growth 3Y
Growth 5Y
Growth 10Y
Dividend Safety Score
Very
Unsafe
Unsafe
Safe
Very
Safe
0
25
50
75
100
Shareholder Yield

Current shareholder yield for Astellas Pharma Inc is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
Lowest
Average
Highest
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

News

Other Videos

Profile

Astellas Pharma Inc Logo
Astellas Pharma Inc

Country

Japan

Industry

Pharmaceuticals

Market Cap

2.8T JPY

Dividend Yield

4.61%

Description

Astellas Pharma, Inc. engages in the research, development, manufacture, import, and export of pharmaceutical products. The company is headquartered in Chuo-Ku, Tokyo-To and currently employs 15,455 full-time employees. The firm mainly operates Pharmaceutical Products business segment. The main products include XTANDI, BETANIS, MIRABETRIC, BETMIGA and new products ZOSPATA, EVERENZO and ENHOLTUMAB VEDOTIN, among others.

Contact

TOKYO-TO
Chuo-Ku
2-5-1, Nihombashihon-cho
+81332443000.0
www.astellas.com

IPO

1949-05-16

Employees

15 455

Officers

President, CEO & Director
Mr. Naoki Okamura BSc
Senior Executive Officer & CFO
Mr. Atsushi Kitamura
General Manager of Finance & Accounting Department
Nobue Yasuda
Chief Scientific Officer & Senior Managing Executive Officer
Mr. Yoshitsugu Shitaka Ph.D.
General Counsel
Ms. Catherine B. Levitt
Chief People Officer, Chief Ethics & Compliance Officer, EVP of HR and Representative Director
Mr. Katsuyoshi Sugita
Show More
Vice President of Corporate Communications
Mr. Stig Ogata
Senior VP and Head of Ethics & Compliance
Ms. Tatjana Dragovic
President of Japan Commercial & Senior Corporate Executive
Mr. Nobuaki Tanaka
Senior Executive Officer & Head of Japan Commercial
Jun Kono
Show Less

See Also

Discover More
What is the Intrinsic Value of one Astellas Pharma Inc stock?

The intrinsic value of one Astellas Pharma Inc stock under the Base Case scenario is 1 795.96 JPY.

Is Astellas Pharma Inc stock undervalued or overvalued?

Compared to the current market price of 1 562 JPY, Astellas Pharma Inc is Undervalued by 13%.

Back to Top